↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Hodgson S) srt2:(1997-1999)"

Search: WFRF:(Hodgson S) > (1997-1999)

Result 1-2 of 2

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Campieri, M, et al. (author) Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group 1997 In: Gut. - : BMJ. - 0017-5749 .- 1468-3288. ; 41:2, s. 209-214 Journal article (peer-reviewed)abstract Background—The use of corticosteroids in active Crohn’s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first pass liver metabolism.Aims—To compare the efficacy and safety of two dosage regimens of budesonide and prednisolone in patients with active Crohn’s disease affecting the ileum and/or the ascending colon.Patients and methods—One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets 40 mg once daily. The treatment period was 12 weeks. The primary efficacy variable was clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) of 150 or less.Results—After eight weeks of treatment, remission occurred in 60% of patients receiving budesonide once daily or prednisolone and in 42% of those receiving budesonide twice daily (p=0.062). The presence of glucocorticoid associated side effects was similar in all groups; however, moon face was more common in the prednisolone group (p=0.0005). The highest frequency of impaired adrenal function, as measured by a short ACTH test, was found in the prednisolone group (p=0.0023).Conclusions—Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn’s disease. The single dose administration is as promptly effective as prednisolone and represents a simpler and safer therapeutic approach, with a considerable reduction in side effects.
2.	Møller, P, et al. (author) Guidelines for follow-up of women at high risk for inherited breast cancer : consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer 1999 In: Disease Markers. - 0278-0240. ; 15:1-3, s. 11-207 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-2 of 2

Refine your search

Type of publication: journal article (2)

Type of content: peer-reviewed (2)

Author/Editor: Olsson, Håkan (1); Smith, P. (1); Möller, P. (1); Lofberg, R (1); Chang-Claude, J (1); Eccles, D (1); show more...; Borg, Åke (1); Florin, T (1); Rutgeerts, P (1); Anderson, E (1); Persson, T (1); Danielsson, A. (1); Evans, G (1); Lalloo, F (1); Caligo, M. (1); Hodgson, S. (1); Morrison, P. J. (1); Stoppa-Lyonnet, D. (1); Nilsson, LG (1); Maehle, L (1); Vasen, H (1); Mani, V (1); Gregory, H (1); Ferguson, A (1); Heimdal, K (1); Sjodahl, R (1); O'Morain, C. (1); Campieri, M (1); Doe, W (1); Malchow, H (1); Prantera, C (1); Selby, W (1); Pallone, F (1); diPietralata, MM (1); Bianchi, P (1); Smallwood, R (1); Lamers, HW (1); TasmanJones, C (1); Hunter, JO (1); Hodgson, H (1); Lee, FI (1); Piacitelli, G (1); Giovanni, S (1); Ellis, A (1); Weir, DG (1); Bevilacqua, G (1); Haites, N (1); Apold, J. (1); Steel, C M (1); Reis, M M (1); show less...

University: Lund University (1); Karolinska Institutet (1)

Language: English (2)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view